High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2019.00622
Abstract: Background: Regorafenib improves progression free survival (PFS) in a subset of metastatic colorectal cancer (mCRC) patients, although no biomarkers of efficacy are available. Circulating methylated DNA (cmDNA) assessed by a five-gene panel was previously associated… read more here.
Keywords: metastatic colorectal; cmdna; colorectal cancer; circulating methylated ... See more keywords